- Trial phase
- Phase 1
- Time to market
- Unknown, the drug is in Phase 1 healthy-volunteer testing. If successful through Phase 2 and Phase 3, potential approval would be several years away (likely 2029-2031 at the earliest).
- Why 5/10
- The next hard catalyst is Phase 1 topline proof-of-mechanism data anticipated in Q2 2027 (~6 months from now). This is not a pivotal readout or PDUFA, it is an early safety/PK/PD study in healthy volunteers, so it does not qualify for the 6-7 tier reserved for binary pivotal events. However, EQ504 is now Equillium's lead value driver after itolizumab's Phase 3 failure, and the company has no approved products or revenue, so the data readout is material. Score 5 reflects a mid-stage (Phase 1) asset that is the company's primary focus with a catalyst within ~6 months.
The next hard catalyst is topline Phase 1 proof-of-mechanism data in Q2 2027 (~6 months from now). Positive data showing AhR target engagement and a clean safety profile in healthy volunteers would validate the mechanism and support advancement into a Phase 2 proof-of-concept study in ulcerative colitis patients in H2 2027. Negative safety signals or failure to demonstrate target engagement would severely damage the thesis for a company now entirely dependent on EQ504 after its prior lead failed Phase 3.
Price Chart
Executive Summary
EQ504 is Equillium's oral, colon-targeted aryl hydrocarbon receptor (AhR) modulator in Phase 1 development for ulcerative colitis and potentially other inflammatory diseases. The company dosed the first healthy volunteer on October 26, 2026, triggering a $20M milestone tranche under its August 2025 financing. Topline proof-of-mechanism data is expected in Q2 2027. EQ504 is now Equillium's lead asset after its prior drug itolizumab (EQ001) missed its Phase 3 primary endpoint in acute GVHD and failed to secure FDA breakthrough designation. The company has ~$57M cash (as of June 30, 2026) plus the new $20M, funding operations into 2029. Analyst consensus is Strong Buy with a mean price target of $8.56, but the stock trades near $1.12, reflecting the binary risk of an early-stage, single-asset biotech with no approved products and no revenue.
How It Works
EQ504 is an oral pill designed to activate the aryl hydrocarbon receptor (AhR), a protein that acts like a master switch in the gut to calm inflammation, repair the intestinal lining, and promote immune tolerance, without broadly suppressing the immune system. It is formulated with an enteric coating to release the drug directly in the colon, targeting the site of disease in ulcerative colitis.
Trial Status
The Phase 1 first-in-human trial (NCT07869225) is a randomized, double-blind, placebo-controlled study in approximately 70 healthy volunteers in Australia. It includes single ascending dose (SAD), multiple ascending dose (MAD), and an optional food-effect cohort, testing once-daily oral doses from 0.1 to 3.0 mg. The first subject was dosed on October 26, 2026. Topline proof-of-mechanism data is expected in Q2 2027. A Phase 2 proof-of-concept study in ulcerative colitis patients is planned for the second half of 2027, contingent on Phase 1 results.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 topline proof-of-mechanism data expected Q2 2027
- Potential Phase 2 proof-of-concept study initiation in ulcerative colitis patients in H2 2027 (contingent on Phase 1 results)
- Q3 2026 earnings report on November 11, 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Equillium, Inc. Press Release EQ ·Originating report